|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Boston Scientific Corporation (BSX), a manufacturer of medical device products for interventional medical specialties. |
|---|---|
| Transferring Party | Rubicon Medical Corporation, a manufacturer of interventional vascular products. |
| Sector | Medical Devices |
| Date | June 15, 2005 |
| Analysis Rubicon's filter, designed to capture and remove dislodged embolic material, synergizes with other Boston Scientific interventional products, including the Taxus drug-eluding stent. The deal, which closed, was previously announced and executed via tender offer and back-end merger. Value -- $71.7 million, plus $83.7 million more if certain milestones are met. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |